Glooko has secured US Food and Drug Administration (FDA) clearance for EndoTool IV Cloud, priming the cloud-based insulin dosing platform for commercialisation across hospital settings.

Glooko has received U.S. FDA 510(k) clearance for EndoTool IV Cloud, making it the first cloud-based, patient-specific insulin dosing platform cleared for hospital use.

Glooko has won FDA clearance for EndoTool IV Cloud, a cloud-based patient-specific insulin dosing platform that supports individualized insulin dosing for hospitalized patients requiring intravenous insulin therapy.

Glooko announced that the FDA granted 510(k) clearance for its EndoTool IV Cloud, a cloud-based, patient-specific insulin dosing platform.

The US FDA cleared the EndoTool IV Cloud, a cloud-based version of parent company Glooko’s inpatient intravenous insulin dosing decision-support platform, through the 510(k) pathway.

Glooko and MyLife Diabetes Care announced that they agreed to expand their partnership centered around diabetes management products.

Data presented at the 2026 AACE Annual Meeting showed that EndoTool IV, Glooko’s inpatient glycemic management solution, achieved an impressive 98% reduction in severe hypoglycemia across a 19-hospital system compared to its historical paper protocols.

Glooko sponsored the second annual Diabetes Dash 5K Run, organized by the Dartmouth Diabetes Initiative, which raised over $8,500 for diabetes education.